We will describe the complex modi operandi of canonical and atypical Bcl-2 proteins, discuss current strategies to modulate the activity of critical family members for the treatment of malignant glioma, and conclude with an outlook on future challenges to conclusively translate such basic and translational knowledge into clinical application. Here, BCL2 is linked to malignant glioma.